Skip to main content

Combinatorial immunization strategy to educate the immune system towards cross recognition and coverage against antigenic drift in seasonal influenza virus exposure

Objective

As current influenza vaccines only afford limited protection against seasonal as well as pandemic influenza, and require regular updating, the development of a “universal” influenza vaccine that can provide broad coverage against different strains within a subtype or even across subtypes has become a key health care priority in both industrialized and low and middle income countries. EDUFLUVAC aims to develop an influenza vaccine that educates the immune system to recognise common influenza epitopes, using a combination of influenza haemagglutinin (HA) antigens delivered on a single virus-like particle. This vaccine concept, using the proven, modern technology of baculovirus VLPs will enable enhanced cross linking of B-cell receptors and favour induction of B-cell responses against common epitopes essential for long-lasting cross recognition and protection. The mechanism underlying the broadening of antibody responses is the increased relative concentration of common epitopes diluting out strain specific epitopes. This will be achieved by testing the ability of a combination of historic HA variants to protect against a variety of modern isolates. A similar approach for developing a novel vaccine for pandemic use will be tested. The knowledge generated will provide Proof of Principle in relevant animal models for an influenza vaccine that does not have to be updated annually, does not have to be manufactured on an annual basis and will not require an annual vaccination campaign. It will also provide for an economically viable large scale production platform for influenza vaccine which, in the event of a pandemic, can manufacture rapidly high quantities of vaccine. All industrial partners (including two SMEs) will benefit from the compilation of the regulatory dossier for transfer to larger vaccine companies and the deeper knowledge integration emanating from EDUFLUVAC in a $2.8 billion global annual influenza vaccine market.

Call for proposal

FP7-HEALTH-2013-INNOVATION-1
See other projects for this call

Coordinator

EUROPEAN VACCINE INITIATIVE EWIV
Address
Vossstrasse 2 Geb 4040
69115 Heidelberg
Germany
Activity type
Research Organisations
EU contribution
€ 930 000
Administrative Contact
Odile Leroy (Dr.)

Participants (6)

REDBIOTEC AG
Switzerland
EU contribution
€ 716 780
Address
Wagistrasse 23
8952 Schlieren
Activity type
Private for-profit entities (excluding Higher or Secondary Education Establishments)
Administrative Contact
Christian Schaub (Mr.)
INSTITUTO DE BIOLOGIA EXPERIMENTAL E TECNOLOGICA
Portugal
EU contribution
€ 1 263 336
Address
Avenida Da Republica Quinta Do Marques
2781-901 Oeiras
Activity type
Research Organisations
Administrative Contact
Elsa Vieira (Dr.)
ETNA BIOTECH SRL
Italy
EU contribution
€ 240 000
Address
Strada Vincenzo Lancia 57
95100 Catania
Activity type
Private for-profit entities (excluding Higher or Secondary Education Establishments)
Administrative Contact
Antonio Di Mauro (Mr.)
STICHTING BIOMEDICAL PRIMATE RESEARCH CENTER
Netherlands
EU contribution
€ 983 670
Address
Lange Kleiweg 161
2288 GJ Rijswijk Zh
Activity type
Research Organisations
Administrative Contact
Willem Slingerland (Mr.)
STICHTING WAGENINGEN RESEARCH
Netherlands
EU contribution
€ 374 250
Address
Droevendaalsesteeg 4
6708 PB Wageningen
Activity type
Research Organisations
Administrative Contact
Norbert Stockhofe (Dr.)
Department of Health
United Kingdom
EU contribution
€ 139 113
Address
Quarry House, Quarry Hill
LS2 7UE Leeds
Activity type
Research Organisations
Administrative Contact
Amanda King (Mrs.)